Cargando…
Bortezomib alleviates antibody‐mediated rejection in kidney transplantation by facilitating Atg5 expression
Antibody‐mediated rejection (AMR) is one of the most dominant mechanisms responsible for the loss of kidney grafts. Previous researches have shown that donor‐specific antibodies (DSAs) are the major mediators of AMR. In order to prolong the survival time of grafts, it is vital to reduce the incidenc...
Autores principales: | Cheng, Hong, Xu, Bin, Zhang, Lijie, Wang, Yi, Chen, Ming, Chen, Shuqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642675/ https://www.ncbi.nlm.nih.gov/pubmed/34734681 http://dx.doi.org/10.1111/jcmm.16998 |
Ejemplares similares
-
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
por: Lee, Juhan, et al.
Publicado: (2015) -
Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation
por: Iesari, Samuele, et al.
Publicado: (2017) -
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial
por: Eskandary, Farsad, et al.
Publicado: (2014) -
Bortezomib: A New Promising Therapy for Early Antibody-Mediated Rejection After Liver Transplantation?
por: Chedid, Marcio F., et al.
Publicado: (2019) -
Antibody-Mediated Rejection in Kidney Transplantation: A Review
por: Puttarajappa, Chethan, et al.
Publicado: (2012)